View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 11, 2011

Gilead Joins Medicines Patent Pool

Gilead Sciences has signed up to the Medicines Patent Pool to improve access to HIV treatments in developing countries, becoming the first pharmaceutical firm to do so. Founded in 2010, the Medicines Patent Pool enables drug manufacturers to produce cheaper, generic versions of drugs

By cms admin

Gilead Sciences has signed up to the Medicines Patent Pool to improve access to HIV treatments in developing countries, becoming the first pharmaceutical firm to do so.

Founded in 2010, the Medicines Patent Pool enables drug manufacturers to produce cheaper, generic versions of drugs currently under patents for use in developing or poorer countries.

Gilead will now produce generic version of Viread and Emtriva, both used in the treatment of AIDs and Hepatitis, as well as two pipeline treatments, cobicistat and elvitegravir.

Licences distributed will allow the supply of both Viread and Emtriva in 111 countries, cobicistat in 102 countries and elvitegravir in 99 countries, with patent holders receiving small-scale royalties for their licensed technologies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology